Becton, Dickinson and Company $BDX Shares Sold by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,218 shares of the medical instruments supplier’s stock after selling 785 shares during the period. YHB Investment Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $1,416,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. REAP Financial Group LLC raised its position in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares during the last quarter. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Finally, Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock valued at $551,536 over the last three months. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on BDX shares. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Argus lifted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Barclays lowered their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research note on Tuesday, June 3rd. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $213.30.

Becton, Dickinson and Company Stock Down 0.6%

Shares of NYSE BDX opened at $187.27 on Friday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The firm has a fifty day moving average of $187.65 and a 200-day moving average of $190.39. The stock has a market capitalization of $53.68 billion, a PE ratio of 33.68, a P/E/G ratio of 1.52 and a beta of 0.27. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the previous year, the company earned $3.50 EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.